We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-13.26%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.83B
AUM Growth
-$2.02B
Cap. Flow
-$868M
Cap. Flow %
-17.97%
Top 10 Hldgs %
38.68%
Holding
126
New
2
Increased
20
Reduced
30
Closed
20

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$61.8M
2
MASI
Masimo
MASI
+$53.3M
3
CCCC icon
C4 Therapeutics
CCCC
+$49.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$28.5M
5
TSVT
2seventy bio
TSVT
+$20.9M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$423M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$112M
3
APLS
Apellis Pharmaceuticals
APLS
+$85.6M
4
ITOS
iTeos Therapeutics
ITOS
+$67.7M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$59.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$37.3B
$275M 5.69%
1,683,362
-292,517
-15% -$44.6M
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$365M
$251M 5.19%
15,802,802
– –
TMO icon
3
Thermo Fisher Scientific
TMO
$211B
$220M 4.56%
373,000
-62,500
-14% -$35.9M
PTCT icon
4
PTC Therapeutics
PTCT
$6.51B
$195M 4.03%
5,221,228
-72,738
-1% -$2.8M
ILMN icon
5
Illumina
ILMN
$29.3B
$178M 3.68%
523,638
+19,508
+4% +$6.59M
MASI
6
DELISTED
Masimo
MASI
$164M 3.4%
1,127,593
+277,622
+33% +$53.3M
ESTA icon
7
Establishment Labs
ESTA
$2.77B
$156M 3.23%
2,319,138
– –
VCEL icon
8
Vericel Corp
VCEL
$2.35B
$154M 3.18%
4,017,570
-500,000
-11% -$18M
PEN icon
9
Penumbra
PEN
$12.6B
$148M 3.06%
665,871
+45,000
+7% +$10M
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$128M 2.66%
1,561,497
– –
GMED icon
11
Globus Medical
GMED
$10.6B
$124M 2.57%
1,682,291
+11,480
+0.7% +$798K
TNDM icon
12
Tandem Diabetes Care
TNDM
$1.16B
$117M 2.42%
1,004,936
-155,798
-13% -$18.2M
PTGX icon
13
Protagonist Therapeutics
PTGX
$8.99B
$114M 2.35%
4,794,499
+2,194,677
+84% +$61.8M
CCCC icon
14
C4 Therapeutics
CCCC
$389M
$110M 2.28%
4,531,982
+2,037,017
+82% +$49.5M
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
$109M 2.26%
1,743,864
-200,000
-10% -$10.8M
ARGX icon
16
argenx
ARGX
$57.5B
$106M 2.2%
336,978
+19,531
+6% +$5.68M
CUTR
17
DELISTED
Cutera, Inc.
CUTR
$105M 2.18%
1,526,263
+129,200
+9% +$5.22M
CLDX icon
18
Celldex Therapeutics
CLDX
$2.84B
$105M 2.17%
3,084,215
-837,364
-21% -$26.8M
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$104M 2.16%
2,757,947
-506,084
-16% -$20M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.73B
$99.7M 2.06%
1,373,284
– –
CYTK icon
21
Cytokinetics
CYTK
$11.1B
$94.3M 1.95%
2,561,182
– –
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$88.6M 1.83%
4,795,000
– –
FULC icon
23
Fulcrum Therapeutics
FULC
$253M
$85.4M 1.77%
3,611,194
-255,678
-7% -$3.62M
PMVP icon
24
PMV Pharmaceuticals
PMVP
$64.5M
$80.6M 1.67%
3,872,154
+891,194
+30% +$15.7M
NTRA icon
25
Natera
NTRA
$37.9B
$78M 1.61%
1,917,283
+55,049
+3% +$3.31M
1
2 3 4 5

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q1 2022 Portfolio in Review

As of Q1 2022, RTW Investments held 126 positions worth $4.83B, down 29% from $6.85B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

RTW Investments withdrew a net $868M in Q1 2022, closing 20 positions and reducing 30 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $423M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, RTW Investments opened a new position in CinCor Pharma, Inc. Common Stock worth $24.4M.

  • RTW Investments's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 1,389,705 shares worth $24.4M.
  • RTW Investments added most to Protagonist Therapeutics in Q1 2022, an estimated $61.8M increase.
  • RTW Investments's biggest Q1 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $85.6M.
  • RTW Investments fully exited State Street SPDR S&P 500 ETF Trust in Q1 2022, selling an estimated $423M.
  • RTW Investments's ten largest holdings make up 39% of its $4.83B portfolio in Q1 2022.
  • RTW Investments opened 2 new positions and closed 20 in Q1 2022.
  • RTW Investments's portfolio value fell 29% quarter-over-quarter to $4.83B.

Based on RTW Investments's 13F filing for Q1 2022, filed 16 May 2022.